In Opthea’s SEC filing related to its planned IPO, the company has also announced plans to develop a co-formulation of OPT-302 with an approved and/or biosimilar anti-VEGF-A therapy. It is expected that an IND will be filed next year.
http://archive.fast-edgar.com/20200924/A82LC22EZZ2R82Z222J92WYPJ8SDZZ22X222/
In Opthea’s SEC filing related to its planned IPO, the company...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $409.3M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 37.5¢ | 37.0¢ | $922.2K | 2.465M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 262769 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 1 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |